These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28739636)

  • 1. Immunoassay for human serum erythroferrone.
    Ganz T; Jung G; Naeim A; Ginzburg Y; Pakbaz Z; Walter PB; Kautz L; Nemeth E
    Blood; 2017 Sep; 130(10):1243-1246. PubMed ID: 28739636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of erythroferrone suppression by transfusion on the erythropoietin-erythroferrone-hepcidin axis in transfusion-dependent thalassaemia: A pre-post cohort study.
    Zaman BA; Rasool SO; Abdo JM
    Br J Haematol; 2023 May; 201(3):547-551. PubMed ID: 36535905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.
    Pirotte M; Fillet M; Seidel L; Jaspers A; Baron F; Beguin Y
    Am J Hematol; 2021 Oct; 96(10):1275-1286. PubMed ID: 34310730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia.
    El-Gamal RAE; Abdel-Messih IY; Habashy DM; Zaiema SEG; Pessar SA
    Ann Hematol; 2020 Jan; 99(1):31-39. PubMed ID: 31834456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.
    Srole DN; Ganz T
    J Cell Physiol; 2021 Jul; 236(7):4888-4901. PubMed ID: 33372284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythroferrone as a sensitive biomarker to detect stimulation of erythropoiesis.
    Ramirez Cuevas K; Schobinger C; Gottardo E; Voss SC; Kuuranne T; Tissot JD; Favrat B; Townsend N; Leuenberger N
    Drug Test Anal; 2020 Feb; 12(2):261-267. PubMed ID: 31655016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoiesis and Iron Parameters in Transfusion-dependent and Nontransfusion-dependent Thalassemias.
    Ozturk Z; Gumuslu S; Yalcin K; Kupesiz A
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):186-192. PubMed ID: 34157011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone.
    Diepeveen L; Roelofs R; Grebenchtchikov N; van Swelm R; Kautz L; Swinkels D
    PLoS One; 2021; 16(7):e0254851. PubMed ID: 34283879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietic regulators of iron metabolism.
    Ganz T
    Free Radic Biol Med; 2019 Mar; 133():69-74. PubMed ID: 29981834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
    Olivera J; Zhang V; Nemeth E; Ganz T
    Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marathon Run-induced Changes in the Erythropoietin-Erythroferrone-Hepcidin Axis are Iron Dependent.
    Tomczyk M; Kortas J; Flis D; Kaczorowska-Hac B; Grzybkowska A; Borkowska A; Lewicka E; Dabrowska-Kugacka A; Antosiewicz J
    Int J Environ Res Public Health; 2020 Apr; 17(8):. PubMed ID: 32316587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Erythroferrone, Hepcidin, and Iron Overload Status in Iraqi Transfusion-Dependent β-Thalassemia Major Patients.
    Smesam HNK; Albuthabhak HAQ; Arjmand S; Al-Hakeim HK; R Siadat SO
    Hemoglobin; 2020 Jul; 44(4):272-277. PubMed ID: 32718192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations.
    Schotten N; Laarakkers CM; Roelofs RW; Origa R; van Kraaij MG; Swinkels DW
    Am J Hematol; 2017 Mar; 92(3):E29-E31. PubMed ID: 28033686
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
    Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T
    Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia.
    Arezes J; Foy N; McHugh K; Quinkert D; Benard S; Sawant A; Frost JN; Armitage AE; Pasricha SR; Lim PJ; Tam MS; Lavallie E; Pittman DD; Cunningham O; Lambert M; Murphy JE; Draper SJ; Jasuja R; Drakesmith H
    Blood; 2020 Feb; 135(8):547-557. PubMed ID: 31899794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between growth differentiation factor-15, erythroferrone, and iron status in thalassemic patients.
    Youssry I; Samy RM; AbdelMohsen M; Salama NM
    Pediatr Res; 2024 Mar; 95(4):1095-1100. PubMed ID: 37464096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial.
    Breenfeldt Andersen A; Bonne TC; Bejder J; Jung G; Ganz T; Nemeth E; Olsen NV; Huertas JR; Nordsborg NB
    Am J Physiol Regul Integr Comp Physiol; 2021 Aug; 321(2):R152-R161. PubMed ID: 34160288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Umbilical Cord Erythroferrone Is Inversely Associated with Hepcidin, but Does Not Capture the Most Variability in Iron Status of Neonates Born to Teens Carrying Singletons and Women Carrying Multiples.
    Delaney KM; Guillet R; Pressman EK; Ganz T; Nemeth E; O'Brien KO
    J Nutr; 2021 Sep; 151(9):2590-2600. PubMed ID: 34236433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the erythropoietin-erythroferrone-hepcidin axis intact in human neonates?
    Bahr TM; Ward DM; Jia X; Ohls RK; German KR; Christensen RD
    Blood Cells Mol Dis; 2021 May; 88():102536. PubMed ID: 33450539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
    Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
    PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.